步長製藥(603858.SH):子公司簽訂技術服務(委託)合同
格隆匯12月6日丨步長製藥(603858.SH)公佈,全資子公司保定天浩製藥有限公司與鄭州深藍海生物醫藥科技有限公司簽訂《技術服務(委託)合同》,委託深藍海醫藥在國內GCP基地醫院開展“比較BC003和新活素治療急性失代償性心力衰竭(ADHF)患者的有效性及安全性的多中心、隨機、雙盲、陽性對照的Ⅲ期臨牀研究”,按照我國現行《藥物臨牀試驗質量管理規範(GCP)》和《藥品註冊管理辦法》及經保定天浩認可和組長單位共同確定的實驗方案進行該試驗組織與實施工作。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.